PMC6050796_01
Peripheral blood smear showing 3 medium to large prolymphocytes with moderate
basophilic cytoplasm, indented nuclei, and prominent vesicular nucleoli.
These prolymphocytes account for >55% of the circulating cells.
10.1177_2324709618788674-fig1.jpg
PMC6050796_01_10.1177_2324709618788674-fig1.jpg
fig1-2324709618788674
The peripheral smear showed abundant prolymphocytes (Figure 1).
Bone marrow biopsy shows a marrow diffusely infiltrated by predominantly
CD20-positive B-lymphocytes accounting for about 50% of marrow cellularity.
B- and T-lymphocyte ratio is estimated to be 2:1. The infiltration is
interstitial and with focal micronodularity.
10.1177_2324709618788674-fig2.jpg
PMC6050796_01_10.1177_2324709618788674-fig2.jpg
fig2-2324709618788674
These lymphocytes accounted for about 50% of marrow cellularity, with B- and T-lymphocyte ratio estimated to be 2:1 (Figure 2).
Positron emission tomography/computed tomography at the time of diagnosis and
prior to the initiation of treatment. The spleen is massively enlarged,
measuring 29.2 x 11.4 x 11.7 cm. There is homogeneous density and
homogeneous FDG activity similar to the liver with a maximum SUV of 2.6.
10.1177_2324709618788674-fig3.jpg
PMC6050796_01_10.1177_2324709618788674-fig3.jpg
fig3-2324709618788674
A positron emission tomography (PET) scan revealed the spleen to be massively enlarged measuring 29 x 12 x 8 cm with significant mass effect on the intra-abdominal contents, with displacement of the left kidney to the midline and compression of the colonic splenic flexure (Figure 3).
PMC6050796_02
Positron emission tomography/computed tomography showing disease progression
after treatment with rituximab and bendamustine. The study was done prior to
her initial treatment with obinutuzumab and chlorambucil. There is interval
development of bilateral cervical, mediastinal, and periportal adenopathy.
The spleen is massively enlarged measuring 29 x 12 x 8 cm. There is diffuse
increased uptake within the spleen with maximum SUV being 3.2.
10.1177_2324709618788674-fig4.jpg
PMC6050796_02_10.1177_2324709618788674-fig4.jpg
fig4-2324709618788674
She also developed bilateral pleural effusions (Figure 4).
Positron emission tomography/computed tomography after 4 cycles of treatment
with obinutuzumab and chlorambucil. The spleen is decreased in size compared
with prior study, now measuring approximately 18.5 x 10.0 x 7.3 cm and
decreased in uptake with maximum SUV now measuring 1.9, which is slightly
above blood pool and less than liver uptake.
10.1177_2324709618788674-fig5.jpg
PMC6050796_02_10.1177_2324709618788674-fig5.jpg
fig5-2324709618788674
A repeat posttreatment PET scan showed a decreased spleen size, which measured approximately 18.5 x 10.0 x 7.3 cm, and her lymphadenopathy and pleural effusions had resolved (Figure 5).